Rifaximin on epigenetics and autophagy in animal model of hepatocellular carcinoma secondary to metabolic-dysfunction associated steatotic liver disease
| dc.contributor.author | Michalczuk, Matheus Truccolo | pt_BR |
| dc.contributor.author | Longo, Larisse | pt_BR |
| dc.contributor.author | Keingeski, Melina Belén | pt_BR |
| dc.contributor.author | Keingeski, Melina Belén | pt_BR |
| dc.contributor.author | Keingeski, Melina Belén | pt_BR |
| dc.contributor.author | Basso, Bruno Souza | pt_BR |
| dc.contributor.author | Guerreiro, Gabriel Tayguara Silveira | pt_BR |
| dc.contributor.author | Ferrari, Jéssica Tonin | pt_BR |
| dc.contributor.author | Vargas, José Eduardo | pt_BR |
| dc.contributor.author | Oliveira, Claudia Pinto Marques Souza de | pt_BR |
| dc.contributor.author | Cruz, Carolina Uribe | pt_BR |
| dc.contributor.author | Cerski, Carlos Thadeu Schmidt | pt_BR |
| dc.contributor.author | Chiela, Eduardo Cremonese Filippi | pt_BR |
| dc.contributor.author | Álvares-da-Silva, Mário Reis | pt_BR |
| dc.date.accessioned | 2025-11-26T07:56:18Z | pt_BR |
| dc.date.issued | 2024 | pt_BR |
| dc.identifier.issn | 1948-5182 | pt_BR |
| dc.identifier.uri | http://hdl.handle.net/10183/299226 | pt_BR |
| dc.description.abstract | BACKGROUND Prevalence of hepatocellular carcinoma (HCC) is increasing, especially in patients with metabolic dysfunctionassociated steatotic liver disease (MASLD). AIM To investigate rifaximin (RIF) effects on epigenetic/autophagy markers in animals. METHODS Adult Sprague-Dawley rats were randomly assigned (n = 8, each) and treated from 5-16 wk: Control [standard diet, water plus gavage with vehicle (Veh)], HCC [high-fat choline deficient diet (HFCD), diethylnitrosamine (DEN) in drinking water and Veh gavage], and RIF [HFCD, DEN and RIF (50 mg/kg/d) gavage]. Gene expression of epigenetic/autophagy markers and circulating miRNAs were obtained. RESULTS All HCC and RIF animals developed metabolic-dysfunction associated steatohepatitis fibrosis, and cirrhosis, but three RIF-group did not develop HCC. Comparing animals who developed HCC with those who did not, miR-122, miR-34a, tubulin alpha-1c (Tuba-1c), metalloproteinases-2 (Mmp2), and metalloproteinases-9 (Mmp9) were significantly higher in the HCC-group. The opposite occurred with Becn1, coactivator associated arginine methyltransferase- 1 (Carm1), enhancer of zeste homolog-2 (Ezh2), autophagy-related factor LC3A/B (Map1 Lc3b), and p62/ sequestosome-1 (p62/SQSTM1)-protein. Comparing with controls, Map1 Lc3b, Becn1 and Ezh2 were lower in HCC and RIF-groups (P < 0.05). Carm1 was lower in HCC compared to RIF (P < 0.05). Hepatic expression of Mmp9 was higher in HCC in relation to the control; the opposite was observed for p62/Sqstm1 (P < 0.05). Expression of p62/SQSTM1 protein was lower in the RIF-group compared to the control (P = 0.024). There was no difference among groups for Tuba-1c, Aldolase-B, alpha-fetoprotein, and Mmp2 (P > 0.05). miR-122 was higher in HCC, and miR-34a in RIF compared to controls (P < 0.05). miR-26b was lower in HCC compared to RIF, and the inverse was observed for miR-224 (P < 0.05). There was no difference among groups regarding miR-33a, miR-143, miR-155, miR-375 and miR-21 (P > 0.05). CONCLUSION RIF might have a possible beneficial effect on preventing/delaying liver carcinogenesis through epigenetic modulation in a rat model of MASLD-HCC. | en |
| dc.format.mimetype | application/pdf | pt_BR |
| dc.language.iso | eng | pt_BR |
| dc.relation.ispartof | World journal of hepatology. Pleasanton,. Vol. 16, no. 1 (Jan. 2024), p. 75-90 | pt_BR |
| dc.rights | Open Access | en |
| dc.subject | Modelos animais de doenças | pt_BR |
| dc.subject | Animal model | en |
| dc.subject | Autofagia | pt_BR |
| dc.subject | Autophagy | en |
| dc.subject | Epigenômica | pt_BR |
| dc.subject | Epigenetic | en |
| dc.subject | Carcinoma hepatocelular | pt_BR |
| dc.subject | Hepatocellular carcinoma | en |
| dc.subject | Metabolic dysfunction-associated steatotic liver disease | en |
| dc.subject | Rifaximina | pt_BR |
| dc.subject | Rifaximin | en |
| dc.subject | Síndrome metabólica | pt_BR |
| dc.subject | Figado gorduroso | pt_BR |
| dc.title | Rifaximin on epigenetics and autophagy in animal model of hepatocellular carcinoma secondary to metabolic-dysfunction associated steatotic liver disease | pt_BR |
| dc.type | Artigo de periódico | pt_BR |
| dc.identifier.nrb | 001295493 | pt_BR |
| dc.type.origin | Estrangeiro | pt_BR |
Este item está licenciado na Creative Commons License
-
Artigos de Periódicos (44627)Ciências da Saúde (12251)

